📰 Patients Sensitive News
Patients Sensitive News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Patients Sensitive. Real-time updates on events, politics, business and more.
February 22, 2024
Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter Delivered $49.3 million in net income for the full year 2023, including $4.7...
February 15, 2024
Amylyx Pharmaceuticals, Inc. today announced that two abstracts detailing next steps in the development of the Company’s investigational antisense oligonucleotide , AMX0114, for the potential...
December 4, 2023
Amylyx Pharmaceuticals, Inc. today announced the publication of analyses performed on neuroinflammatory biomarkers using plasma samples from participants with amyotrophic lateral sclerosis from...
November 28, 2023
- Dr. Bedrosian brings to Amylyx nearly 30 years of leadership in clinical research, development, and advancing pipeline programs into commercialized global products including as CMO at Ultragenyx,...
November 27, 2023
Amylyx Pharmaceuticals, Inc. today announced that several abstracts detailing data on AMX0035 and the Company’s investigational antisense oligonucleotide, AMX0114, for the potential treatment of...
August 10, 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug 10, 2023--
May 11, 2023
˗ First quarter 2023 product revenue of $71.4 million; commercial launches of RELYVRIO® in U.S. and ALBRIOZA™ in Canada for the treatment of ALS continue to progress ˗... | May 11, 2023
March 14, 2023
Full year product revenue of $22.2 million; commercial launches of RELYVRIO® in U.S. and ALBRIOZA™ in Canada continue to progressRegulatory review ongoing in the EUKaren Firestone, CEO and co-founder of Aureus Asset Management and prior fund manager at Fidelity Investments, appointed to the Company's Board of Direct...